We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-6.88%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.39B
AUM Growth
-$1.88B
Cap. Flow
-$1.67B
Cap. Flow %
-49.21%
Top 10 Hldgs %
42.09%
Holding
110
New
24
Increased
17
Reduced
27
Closed
38

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$163M
2
NXPI icon
NXP Semiconductors
NXPI
+$72.5M
3
PTCT icon
PTC Therapeutics
PTCT
+$72M
4
CI icon
Cigna
CI
+$64.7M
5
SAGE
Sage Therapeutics
SAGE
+$62.5M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$217M
2
HUM icon
Humana
HUM
+$149M
3
ICUI icon
ICU Medical
ICUI
+$97.4M
4
BABA icon
Alibaba
BABA
+$84.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$83.1M

Sector Composition

Rank Sector Weight
1 Healthcare 59.59%
2 Technology 15.32%
3 Financials 1.11%
4 Communication Services 1.02%
5 Consumer Discretionary 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$11.3B
$145M 4.28%
2,149,051
+69,663
+3% +$5.37M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$142M 4.18%
+1,446,612
New +$163M
PEN icon
3
Penumbra
PEN
$12.5B
$138M 4.09%
1,029,564
+257,765
+33% +$39.9M
ZBH icon
4
Zimmer Biomet
ZBH
$17.1B
$136M 4%
1,017,477
-182,982
-15% -$23.6M
GILD icon
5
Gilead Sciences
GILD
$163B
$117M 3.45%
1,843,860
+479,572
+35% +$31.3M
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
$104M 3.07%
2,271,536
+443,158
+24% +$24.9M
XBI icon
7
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$87.2M 2.58%
+1,143,600
New +$95M
IRTC icon
8
iRhythm Holdings
IRTC
$3.47B
$80.1M 2.37%
1,081,059
+398,096
+58% +$30.8M
NXPI icon
9
NXP Semiconductors
NXPI
$70.2B
$77.5M 2.29%
+709,930
New +$72.5M
MCHP icon
10
Microchip Technology
MCHP
$46B
$77.2M 2.28%
1,660,988
+153,930
+10% +$6.98M
AGN
11
DELISTED
Allergan plc
AGN
$76.7M 2.26%
455,598
-1,329,999
-74% -$217M
IQV icon
12
IQVIA
IQV
$33.6B
$71.3M 2.1%
477,002
-161,324
-25% -$25.1M
WCG
13
DELISTED
Wellcare Health Plans, Inc.
WCG
$68.3M 2.02%
263,626
-216,618
-45% -$59.8M
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$65.1M 1.92%
2,315,938
-912,741
-28% -$31.2M
MYOK
15
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$64M 1.89%
1,227,371
-550,038
-31% -$29.2M
DXCM icon
16
DexCom
DXCM
$27.8B
$63.9M 1.89%
1,712,968
+66,184
+4% +$2.57M
CI icon
17
Cigna
CI
$76.7B
$60.4M 1.78%
+397,684
New +$64.7M
NVS icon
18
Novartis
NVS
$293B
$59.7M 1.76%
+689,600
New +$61.9M
TWLO icon
19
Twilio
TWLO
$27.9B
$58.8M 1.74%
534,889
+218,747
+69% +$28.4M
PTCT icon
20
PTC Therapeutics
PTCT
$6.51B
$55.9M 1.65%
+1,654,225
New +$72M
EW icon
21
Edwards Lifesciences
EW
$48.7B
$55.4M 1.63%
755,262
-613,815
-45% -$43.1M
MOH icon
22
Molina Healthcare
MOH
$11.6B
$54M 1.59%
491,797
-49,101
-9% -$6.36M
CTLT
23
DELISTED
CATALENT, INC.
CTLT
$52.7M 1.56%
1,106,773
+489,754
+79% +$26.3M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$52.4M 1.55%
+373,828
New +$62.5M
CRM icon
25
Salesforce
CRM
$134B
$52M 1.54%
350,422
-248,337
-41% -$37.7M
1
2 3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q3 2019 Portfolio in Review

As of Q3 2019, PFM Health Sciences held 110 positions worth $3.39B, down 36% from $5.26B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

PFM Health Sciences withdrew a net $1.67B in Q3 2019, closing 38 positions and reducing 27 holdings. Its most notable exit was Humana, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 55% a quarter earlier, followed by Technology and Financials.

Against the trend, PFM Health Sciences opened a new position in Alexion Pharmaceuticals worth $142M.

  • PFM Health Sciences's largest Q3 2019 buy was Alexion Pharmaceuticals: 1,446,612 shares worth $142M.
  • PFM Health Sciences added most to uniQure in Q3 2019, an estimated $56.8M increase.
  • PFM Health Sciences's biggest Q3 2019 reduction was Allergan plc, cutting an estimated $217M.
  • PFM Health Sciences fully exited Humana in Q3 2019, selling an estimated $149M.
  • PFM Health Sciences's ten largest holdings make up 42% of its $3.39B portfolio in Q3 2019.
  • PFM Health Sciences opened 24 new positions and closed 38 in Q3 2019.
  • PFM Health Sciences's portfolio value fell 36% quarter-over-quarter to $3.39B.

Based on PFM Health Sciences's 13F filing for Q3 2019, filed 14 Nov 2019.